Get the Weekly Intelligence Brief — top committee picks every Sunday.
NASDAQ · STOCK

Gilead Sciences

GILD Healthcare Unknown Updated July 31, 2026
$130.19
52W $108.46 – $157.29
57/100
$161.66B
17.5
0.34
AI Committee Verdict
Buy
Conviction: High · 83% agreement · 6 analysts
+20.8%
-2.0%
10.61:1
High

Is GILD Bullish or Bearish?

Bullish. Innellis AI committee rates Gilead Sciences (GILD) Buy with a composite score of 57/100 , based on 6 analysts with 83% agreement. Last updated July 31, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +18.49 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -1.51 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

Some positive signals exist — eps growing 55.5% yoy — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.

Bull & Bear Case

Bull Case
  • ROE of 42.2% shows genuine earnings power backing the valuation — Value
  • EPS growing 55.5% YoY — Growth
  • 4 consecutive earnings beats -- consistent execution — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Price structure making higher highs and higher lows — Technical
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • Price-to-book of 6.7x prices in significant intangible value — Value
  • MACD histogram negative -- bearish momentum — Technical
  • Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of July 31, 2026
Overall Committee Score
57/100
Agreement
83%
Analysts
6
Conviction
High
Sector Rank
Top 43%
of 93 Healthcare peers
Value Analyst neutral
55 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 42.2% shows genuine earnings power backing the valuation
− Price-to-book of 6.7x prices in significant intangible value
Growth Analyst bullish
72 / 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 55.5% YoY
Technical Analyst neutral
54 / 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Macro Analyst neutral
58 / 100 · Moderate confidence
Macro backdrop is mixed or neutral -- not a strong tailwind or headwind either way
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst neutral
55 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2744.14)
Open Full Terminal →

Investment Thesis Evolution

Committee score weakened from 60.3 to 56.5.

Analyst-level changes:
  • Growth Analyst: score 82->72 (-10); +1 bullish signal(s).
  • Macro Analyst: stance bullish->neutral; score 65->58 (-8); +1 bullish signal(s).
  • Portfolio Manager: +2 bearish signal(s).
  • Value Analyst joined: neutral at 55.

Comparing 2026-07-30 to 2026-07-31 (1 day apart).

Technical Analysis

RSI (14)
44.8
Neutral
MACD Histogram
-0.204
Bearish Momentum
Trend Direction
Uptrend
Weekly: Sideways
Market Structure
Mixed
Support
$127.64
Resistance
$157.26
Bollinger %B
0.29
Inside Bands
Price vs Moving Averages
EMA 9
$131.45 Below
EMA 21
$131.11 Below
EMA 50
$131.00 Below
EMA 200
$129.00 Above

Fundamental Analysis

Valuation
69
Growth
75
Profitability
1
Financial Health
88
Cash Flow
37
Valuation
P/E Ratio 17.5×
P/B Ratio 6.88×
PEG Ratio 0.32
Dividend Yield 0.02%
52W High $157.29
52W Low $108.46
Quality & Growth
ROE 37.5%
ROA 14.4%
Gross Margin 79.3%
Operating Margin 38.3%
Revenue Growth YoY
Debt / Equity 0.94
AI Fundamental Assessment
P/E ratio of 17.5 (inexpensive relative to a 15-40x range); Price-to-book of 6.9x; PEG ratio of 0.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.4%; Return on assets of 0.1%; Net margin of 0.3%; Gross margin of 0.8%; Current ratio of 1.97 (healthy short-term liquidity); Debt-to-equity of 0.94; Free cash flow margin of 0.9% (thin cash generation); Free cash flow per share is positive (8.24); Most recent quarter beat estimates by 4.0%; 4 consecutive earnings beats; EPS growth accelerating (-24.7% -> +9.1% QoQ); Analyst estimates falling over recent quarters
Get the Full GILD Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore GILD Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime